Langerhans cell histiocytosis.
Carlos Rodriguez-Galindo, Carl E Allen
https://pubmed.ncbi.nlm.nih.gov/32106306/Actively Recruiting
Led by West China Second University Hospital · Updated on 2026-02-24
120
Participants Needed
11
Research Sites
N/A
Total Duration
Langerhans cell histiocytosis LCH is a disorder mostly affecting children, caused by an abnormal buildup of Langerhans cells in body tissues. This disease varies widely in severity, with mild cases often resolving on their own and severe multisystem cases involving multiple organs like liver, spleen, or bone marrow, which can be life-threatening without proper treatment. Standard treatment includes prednisone and vinblastine chemotherapy, but some children develop resistance or relapse, leading to long-term health problems. This trial studies whether adding a targeted drug called luvometinib to chemotherapy can improve outcomes in children with multisystem LCH. Participants will be randomly assigned to receive either a modified standard chemotherapy regimen prednisone and vincristine alone or the same chemotherapy combined with oral luvometinib, a MEK12 inhibitor taken daily. The chemotherapy also includes mercaptopurine during maintenance. The study is conducted at multiple centers and aims to evaluate if the combination treatment improves patient outcomes compared to chemotherapy alone. During the trial, children will be closely monitored through clinical and imaging evaluations. Researchers will assess event-free survival over two years, responses at 1 and 3 months after treatment, overall survival, and any treatment-related side effects. Follow-up will include safety assessments and regular check-ups to track disease progression and treatment tolerance throughout the study period.
CONDITIONS
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
X
Xue Tang
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
West China Second University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years
Participants receive either the modified LCH-III chemotherapy regimen combined with oral luvometinib or the modified LCH-III chemotherapy regimen alone.
Regular visits as per treatment schedule
Duration - Up to 2 years
Participants are monitored for event-free survival, response, overall survival, and treatment-related adverse events after treatment completion.
Visits at 1 month and 3 months post-treatment and ongoing follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Carlos Rodriguez-Galindo, Carl E Allen
https://pubmed.ncbi.nlm.nih.gov/32106306/Riccardo Haupt, Vasanta Nanduri, Maria Grazia Calevo...
https://pubmed.ncbi.nlm.nih.gov/15049016/Susan J Keam
https://pubmed.ncbi.nlm.nih.gov/40751881/Vivekanudeep Karri, Howard Lin, Jessica Velazquez...
https://pubmed.ncbi.nlm.nih.gov/38501390/Dmitry Evseev, Daria Osipova, Irina Kalinina...
https://pubmed.ncbi.nlm.nih.gov/37216396/James A Whitlock, Birgit Geoerger, Ira J Dunkel...
https://pubmed.ncbi.nlm.nih.gov/36884302/Howard Lin, Akanksha Batajoo, Erin Peckham-Gregory...
https://pubmed.ncbi.nlm.nih.gov/40167581/Xin-Xin Cao, Qi Zhu, Zhen Cai...
https://pubmed.ncbi.nlm.nih.gov/41035796/Camille Bigenwald, Jessica Le Berichel, C Matthias Wilk...
https://pubmed.ncbi.nlm.nih.gov/33958797/Eily Cournoyer, Justin Ferrell, Susan Sharp...
https://pubmed.ncbi.nlm.nih.gov/37731389/West China Second University Hospital
Lead Sponsor